Browsing Tag
Ris-Rez
2 posts
GSK’s $1.7bn Hansoh licence looks better after Ris-Rez delivers 18.5-month survival in Phase III lung cancer trial
Hansoh Pharmaceutical Group's risvutatug rezetecan produced median overall survival of 18.5 months against 10.3 months for topotecan, strengthening an asset for which GSK paid $185 million upfront and committed up to $1.525 billion in milestones.
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.